| GUIDANCE/WEBPAGE | DOCUMENT | AGENCY | COUNTRY |
| Guidance on the Management of Clinical Trials during the COVID 19 (Coronavirus) pandemic | Version 4 (04/02/2021) | EMA |  European Union |
| EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines | Rev 3 (16/09/2021) | EMA | European Union |
| Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials | English version (26/06/2020) | EMA | European Union |
| Addendum to the Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic | Date: 25.3.2020 Version: v1 | Federal Agency for Medicines and Health Products |  Belgium |
| Opinion of SÚKL's Department of Clinical Trials on Medicinal Products on Ongoing Clinical Trials and To-Be-Commenced Clinical Trials in Light of the COVID-19 Epidemiological Situation | Opinion | SÚKL |  Czech Republic |
| Covid 19 - Ongoing clinical trials Post-lock down recommendations |
ANSM |  France |
|
| Supplementary recommendations to the document European Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic | v4 (updated 25.02.2021) Clinical Trials during COVID-19 Pandemic |
Bundesinstitut fuer Arzneimittel und Medizinprodukte |  Germany |
| Information on the continuity of clinical trials under COVID-19 (reference to EMA document) (coronavirus) - 25.03.2020 | v1 25.03.2020 |  Hungary |
|
| Guidance on the Management of Clinical Trials during COVID-19 | This guidance was updated on 7 April 2021 (version 8.0) | HRPA |  Ireland |
| Clinical trials’ management in Italy during the COVID-19 (coronavirus disease 19) emergency | Clinical trials’ management in Italy during the COVID-19 (coronavirus disease 19) emergency - V3 17/09/2020 | AIFA |  Italy |
| Management of Clinical Trials in relation to covid-19 | Updated 19.03.2020 | The Norwegian Medicines Agency NoMA |  Norway |
| Good clinical practice of medicinal products during the COVID-19 pandemic | Information in English posted Fri, 11 January 2021 | REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS |  Poland |
|
CEIC information regarding clinical trials or intervention studies with MD in view of the current conjecture of Covid-19 INFARMED information regarding clinical trials or intervention studies with MD in view of the current conjecture of Covid-19 |
CEIC INFRAMED |
 Portugal |
|
| ŠÚKL GUIDANCE FOR THE CLINICAL TRIALS IN SLOVAKIA DURING THE EXCEPTIONAL COVID-19 SITUATION | Version 1 (2.4. 2020) | SUKL |  Slovakia |
| Medidas excepcionales aplicables a los ensayos clínicos para gestionar los problemas derivados de la emergencia por COVID-19 -- Exceptional measures applicable to clinical trials to manage compliance issues arising from COVID-19 emergency | July 2020 | Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) |  Spain |
|
Joint guidance of Swissmedic and swissethics on the conduct of clinical trials during COVID-19 pandemic Website of Swiss Ethics - with other relevant documents |
Swissmedic / Swissethics |  Switzerland |
|
| Managing clinical trials during coronavirus (COVID-19) | 16 November 2021 | MHRA |  United Kingdom |
| FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic | March 2020, updated on January 27, 2021 | FDA |  USA |
| EF-GCP- Repository of publications for Clinical Trials in relation to COVID-19 | Links to relevant documents in many countries | European Forum of GCP |  Global coverage |
Last update on 12-04-2021.
Disclaimer
-
Documents and web-pages accessible through the links in this repository are the property of their respective owners. All links have been tested when posted and access is at your own risks
-
ECRIN does not own any of the information and data provided
-
ECRIN cannot ensure the accuracy of each the URL provided in this repository
-
ECRIN cannot guarantee that the latest version of the guidance documents are listed
-
ECRIN cannot be held responsible for any misinformation or misuse of the provided information and documents
Legal disclaimer for the COVID-19 Taksforce internet pages.